For Healthcare Professionals Only

Important Safety InformationPrescribing Information
Important Safety InformationPrescribing Information
header pattern

Contact

Connect with
our team

swooshes

Have questions?

If you have any questions about IHEEZO®, call us at: 1-833-4HARROW (442-7769).

You may also complete the form and someone will respond within 24 business hours.

swooshes
swooshes

By clicking “Submit,” I authorize Harrow, Inc. to send me emails regarding IHEEZO and other informational materials. I understand that I may revoke this authorization and choose not to receive information from Harrow by clicking the “unsubscribe” link provided in emails I receive from Harrow. I have read and understand Harrow's Privacy Notice.

*Required field

Approved Use

IHEEZO® is indicated for ocular surface anesthesia.

Important Safety Information

IHEEZO is contraindicated in patients with a history of hypersensitivity to any component of this preparation.

Approved Use

IHEEZO® is indicated for ocular surface anesthesia.

Important Safety Information

IHEEZO is contraindicated in patients with a history of hypersensitivity to any component of this preparation.

Approved Use

IHEEZO® is indicated for ocular surface anesthesia.

Important Safety Information

  • IHEEZO is contraindicated in patients with a history of hypersensitivity to any component of this preparation.
  • IHEEZO should not be injected or intraocularly administered.
  • Patients should not touch the eye for at least 10 to 20 minutes after using anesthetic as accidental injuries can occur due to insensitivity of the eye.
  • Prolonged use of a topical ocular anesthetic may produce permanent corneal opacification and ulceration with accompanying visual loss.
  • Do not touch the dropper tip to any surface as this may contaminate the gel.
  • IHEEZO is indicated for administration under the direct supervision of a healthcare provider. IHEEZO is not intended for patient self-administration.
  • The most common adverse reactions in studies following IHEEZO administration (incidence greater than or equal to 5%) were mydriasis, conjunctival hyperemia, and eye irritation.
  • You are encouraged to report suspected adverse reactions to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
  • For additional information about IHEEZO, please see the full Prescribing Information.

Approved Use

IHEEZO® is indicated for ocular surface anesthesia.

Important Safety Information

  • IHEEZO is contraindicated in patients with a history of hypersensitivity to any component of this preparation.
  • IHEEZO should not be injected or intraocularly administered.
  • Patients should not touch the eye for at least 10 to 20 minutes after using anesthetic as accidental injuries can occur due to insensitivity of the eye.
  • Prolonged use of a topical ocular anesthetic may produce permanent corneal opacification and ulceration with accompanying visual loss.
  • Do not touch the dropper tip to any surface as this may contaminate the gel.
  • IHEEZO is indicated for administration under the direct supervision of a healthcare provider. IHEEZO is not intended for patient self-administration.
  • The most common adverse reactions in studies following IHEEZO administration (incidence greater than or equal to 5%) were mydriasis, conjunctival hyperemia, and eye irritation.
  • You are encouraged to report suspected adverse reactions to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
  • For additional information about IHEEZO, please see the full Prescribing Information.

By clicking “Allow All”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.